PAZOPANIB TEVA 400mg tablets medication leaflet

L01EX03 pazopanib • Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Other protein kinase inhibitors

Pazopanibum is an alternative name for pazopanib, a medication used for the treatment of advanced renal cell carcinoma and soft tissue sarcoma. It acts as a tyrosine kinase inhibitor, blocking the growth of blood vessels supplying tumors and slowing cancer progression.

The medication is taken orally, usually once daily, and should be used as directed by your doctor. Regular check-ups are important to monitor the effectiveness of the treatment and any potential side effects.

Side effects may include nausea, diarrhea, high blood pressure, fatigue, or changes in liver function. In rare cases, severe reactions such as liver failure or bleeding may occur.

Patients should inform their doctor about any other medications being used or pre-existing conditions to ensure the safe use of pazopanibum.

General data about PAZOPANIB TEVA 400mg

Substance: pazopanib

Date of last drug list: 01-06-2025

Commercial code: W68757002

Concentration: 400mg

Pharmaceutical form: tablets

Quantity: 60

Product type: generic

Price: 6695.47 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: REMEDICA LTD - CIPRU

Holder: TEVA B.V. - OLANDA

Number: 14404/2022/02

Shelf life: 30 months

Concentrations available for pazopanib

200mg, 400mg

Compensation lists for PAZOPANIB TEVA 400mg TEVA

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

6695.47 RON

6695.47 RON

0.00 RON